These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
146 related articles for article (PubMed ID: 3858973)
1. Development of an oral formulation of omeprazole. Pilbrant A; Cederberg C Scand J Gastroenterol Suppl; 1985; 108():113-20. PubMed ID: 3858973 [TBL] [Abstract][Full Text] [Related]
3. Relative bioavailability and pharmacokinetic study of omeprazole 20 mg enteric-coated tablet in healthy Bangladeshi volunteers. Hasan A; Abul Kalam Azad M; Ullah MA; Mahbub Latif AH; Hasnat A Int J Clin Pharmacol Ther; 2009 Mar; 47(3):215-21. PubMed ID: 19281731 [TBL] [Abstract][Full Text] [Related]
4. Influence of food on the bioavailability of an enteric-coated tablet formulation of omeprazole 20 mg under repeated dose conditions. Thomson AB; Sinclair P; Matisko A; Rosen E; Andersson T; Olofsson B Can J Gastroenterol; 1997; 11(8):663-7. PubMed ID: 9459045 [TBL] [Abstract][Full Text] [Related]
5. Bioavailability and efficacy of omeprazole given orally and by nasogastric tube. Larson C; Cavuto NJ; Flockhart DA; Weinberg RB Dig Dis Sci; 1996 Mar; 41(3):475-9. PubMed ID: 8617118 [TBL] [Abstract][Full Text] [Related]
6. Dissolution of omeprazole from delayed-release solid oral dosage forms. Farinha A; Bica A; Martins JM; Pais JP Drug Dev Ind Pharm; 2000 Jul; 26(7):785-90. PubMed ID: 10872100 [TBL] [Abstract][Full Text] [Related]
7. Bioavailability of omeprazole 20 mg capsules containing omeprazole 22.5% enteric coated pellets versus a reference product in healthy Bangladeshi male subjects: an open-label, single-dose, randomized-sequence, two-way crossover study. Islam MS; Trini AB; Shohag H; Ahmed MU; Maruf AA; Hasnat A Int J Clin Pharmacol Ther; 2011 Dec; 49(12):778-86. PubMed ID: 22122821 [TBL] [Abstract][Full Text] [Related]
8. Interaction of omeprazole with enteric-coated salicylate tablets. Nefesoglu FZ; Ayanoglu-Dülger G; Ulusoy NB; Imeryüz N Int J Clin Pharmacol Ther; 1998 Oct; 36(10):549-53. PubMed ID: 9799060 [TBL] [Abstract][Full Text] [Related]
9. Pharmacodynamics and kinetics of omeprazole MUPS 20 mg and pantoprazole 40 mg during repeated oral administration in Helicobacter pylori-negative subjects. Geus WP; Mathôt RA; Mulder PG; Lamers CB Aliment Pharmacol Ther; 2000 Aug; 14(8):1057-64. PubMed ID: 10930900 [TBL] [Abstract][Full Text] [Related]
10. Design and in vitro/in vivo evaluation of multi-layer film coated pellets for omeprazole. He W; Fan LF; Du Q; Xiang B; Li CL; Bai M; Chang YZ; Cao DY Chem Pharm Bull (Tokyo); 2009 Feb; 57(2):122-8. PubMed ID: 19182399 [TBL] [Abstract][Full Text] [Related]
11. Oral pharmacokinetics of omeprazole and lansoprazole after single and repeated doses as intact capsules or as suspensions in sodium bicarbonate. Sharma VK; Peyton B; Spears T; Raufman JP; Howden CW Aliment Pharmacol Ther; 2000 Jul; 14(7):887-92. PubMed ID: 10886044 [TBL] [Abstract][Full Text] [Related]
12. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions. Chen C; Bujanover S; Kareht S; Rapoport AM Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369 [TBL] [Abstract][Full Text] [Related]
13. Oral bioavailability of omeprazole before and after chronic therapy in patients with duodenal ulcer. Ching MS; Mihaly GW; Angus PW; Morgan DJ; Devenish-Meares S; Yeomans ND; Smallwood RA Br J Clin Pharmacol; 1991 Feb; 31(2):166-70. PubMed ID: 2049231 [TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and metabolism of omeprazole in animals and man--an overview. Regårdh CG; Gabrielsson M; Hoffman KJ; Löfberg I; Skånberg I Scand J Gastroenterol Suppl; 1985; 108():79-94. PubMed ID: 3858978 [TBL] [Abstract][Full Text] [Related]
15. Comparative bioavailability of two enteric-coated capsules of omeprazole in healthy volunteers. Garg SK; Chugh Y; Tripathi SK; Kumar N; Sharma PL Int J Clin Pharmacol Ther Toxicol; 1993 Feb; 31(2):96-9. PubMed ID: 8458683 [TBL] [Abstract][Full Text] [Related]
16. Effect of single and repeated doses of oral omeprazole on gastric acid and pepsin secretion and fasting serum gastrin and serum pepsinogen I levels. Festen HP; Tuynman HA; Défize J; Pals G; Frants RR; Straub JP; Meuwissen SG Dig Dis Sci; 1986 Jun; 31(6):561-6. PubMed ID: 3086061 [TBL] [Abstract][Full Text] [Related]
17. Oral bioavailability of pantoprazole suspended in sodium bicarbonate solution. Ferron GM; Ku S; Abell M; Unruh M; Getsy J; Mayer PR; Paul J Am J Health Syst Pharm; 2003 Jul; 60(13):1324-9. PubMed ID: 12901033 [TBL] [Abstract][Full Text] [Related]
18. Animal pharmacodynamics of omeprazole. A survey of its pharmacological properties in vivo. Larsson H; Mattson H; Sundell G; Carlsson E Scand J Gastroenterol Suppl; 1985; 108():23-35. PubMed ID: 3858975 [TBL] [Abstract][Full Text] [Related]
19. Comparison of the effects of immediate-release omeprazole powder for oral suspension and pantoprazole delayed-release tablets on nocturnal acid breakthrough in patients with symptomatic gastro-oesophageal reflux disease. Castell D; Bagin R; Goldlust B; Major J; Hepburn B Aliment Pharmacol Ther; 2005 Jun; 21(12):1467-74. PubMed ID: 15948814 [TBL] [Abstract][Full Text] [Related]
20. A single-dose, three-period, six-sequence crossover study comparing the bioavailability of solution, suspension, and enteric-coated tablets of magnesium valproate in healthy Mexican volunteers under fasting conditions. Marcelín-Jiménez G; Angeles-Moreno AP; Contreras-Zavala L; Morales-Martínez M; Rivera-Espinosa L Clin Ther; 2009 Sep; 31(9):2002-11. PubMed ID: 19843490 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]